Persistent Ovarian Endometrial Stromal Sarcoma

Nancy Jo Bush

Joyce P. Griffin-Sobel

ONF 2004, 31(3), 513-514. DOI: 10.1188/04.ONF.513-514

Jump to a section


    Finkler, N.J., & Holloway, R.W. (2002). A phase I/II trial of weekly topotecan in the treatment of advanced recurrent metastatic endometrial carcinoma [Abstract]. Proceedings of the American Society of Clinical Oncology, 21, 171b.

    Fiorica, J., Holloway, R., Ndubisi, B., Orr, J., Grendys, E., Boothby, R., et al. (2002). Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecologic Oncology, 85, 89-94.

    Morris, R., & Munkarah, A. (2002). Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. Oncologist, 7(Suppl. 5), 29-35.

    Sutton, G., Blessing, J.A., Park, R., DiSaia, P.J., & Rosenshein, N. (1996). Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: A study of the Gynecologic Oncology Group. Obstetrics and Gynecology, 87, 747-750.